









UNIVERSITAT.

## EBUS IN CN0-1 NSCLC

Jose Sanz-Santos

Pulmonary Department. Hospital Mútua Terrassa. Terrassa (Barcelona). Spain

Current guidelines for non-small cell lung cancer (NSCLC) mediastinal staging<sup>1,2</sup> recommend starting with non-invasive image-based techniques such as computed tomography (CT) and positron emission tomography (PET) alone or in combination (PET/CT). However, positive and most of the negative results of PET/CT need to be confirmed by means of invasive techniques. More specifically, three clinical situations of normal mediastinum on PET/CT have been related with high risk to occult nodal mediastinal metastases: tumors with clinical (c) size  $\geq$  3 cm ( $\geq$ T2) tumors), cN1 nodal disease on PET/CT and centrally located nodules (central cT1N0M0).

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive technique that is currently recommended by the guidelines as a first-choice technique for invasive mediastinal staging<sup>1,2</sup>. The reported sensitivity of EBUS-TBNA for NSCLC mediastinal staging depends on the appearance of the mediastinum on PET/CT3. A metaanalysis of Gu et al.<sup>3</sup> showed differences of sensitivity of EBUS-TBNA for mediastinal staging between patients with normal (76%) and abnormal (94%) mediastinum on PET/CT. More recently, two meta-analyses<sup>4,5</sup>, focused on EBUS-TBNA for NSCLC mediastinal staging in patients with normal mediastinum on PET/CT, showed a pooled sensitivity of EBUS-TBNA of 49%, that is significantly lower than that reported for overall patients with NSCLC<sup>3</sup>. The role of EBUS-TBNA for each specific clinical scenario of normal mediastinum on PET/CT where invasive staging is recommended (cN1,  $\geq$ T2, and central cT1N0M0) has been scarcely studied. Only two studies<sup>6-7</sup> investigated the usefulness of endosonography in cN1 tumors, both with a reported sensitivity of 38%. One recent study focused on patients with central cT1N0M0 tumors showed a sensitivity of 66%<sup>8</sup>. In conclusion, the diagnostic performance of EBUS-TBNA in patients with tumors cN0/N1 is poorer than in patients with abnormal mediastinum. The indication of EBUS-TBNA as a first-choice procedure in some of these clinical scenarios should be considered.

## **REFERENCES**:

1. De Leyn P, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014; 45:787-98.

2. Silvestri GA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e211S-e250S.

3. Gu P, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer 2009;45(8):1389-96.

4. El-Osta H, et al. Endobronchial ultrasound for nodal staging of patients with non-smallcell lung cancer with radiologically normal mediastinum. A meta-analysis. Ann Am Thorac Soc. 2018; 15:864-874.

5. Leong TL, et al. Preoperative staging by EBUS in cN0/N1 lung cancer: systematic review and meta-analysis. J Bronchology Interv Pulmonol. 2019; 26:155-165.

6. Dooms C, Tournoy KG, Schuurbiers O, et al. Endosonography for mediastinal nodal staging of clinical N1 non-small cell lung cancer: a prospective multicenter study. Chest 2015; 147:209-215.

7. Kim BG, et al. Diagnostic Performance of Endosonography to Detect Mediastinal Lymph Node Metastasis in Patients with Radiological N1 Non-Small Cell Lung Cancer. Cancer Res Treat. 2023; 55:832-840.

8. Serra Mitjà P, et al. EBUS-TBNA for mediastinal staging of centrally located T1N0M0 non-small cell lung cancer clinically staged with PET/CT. Respirology. 2024 Feb;29(2):158-165.